Nanotherapeutics, Inc. Announces Enrollment of First Patient in Phase II Cervical Cancer Trial for Triapine

04-11-2013 Business Wire HealthComments (0)

Biotechnology

Nanotherapeutics, Inc. announced today enrollment of the first patient into a Phase II cervical cancer trial for Triapine®, sponsored by the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI). Triapine® is a ribonucleotidereductase inhibitor (RNRi) that is under evaluation in combination with cisplatin and radiation as a radiosensitizing chemotherapeutic agent for women with advanced stage cervical and vaginal cancers. NCI and Nanotherape

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top